Intravenous Thrombolysis in Anticoagulated and Thrombocytopenic Ischemic Stroke Patients Does Not Increase the Risk of Intracerebral Hemorrhage (P4.271)

Conclusions:These data suggest that IV rt-PA can be safely administered in coagulopathic and thrombocytopenic patients. Although rates of sICH and mortality were similar to the NINDS cohort, caution may be needed to identify certain hemorrhagic risk factors. Routine exclusion of anticoagulated or thrombocytopenic patients is not supported and the use of IV rt-PA in these patients may increase the eligibility for acute stroke therapy, particularly at institutions where IA therapy is unavailable.Disclosure: Dr. Barazangi has received personal compensation for activities with Genentech. Dr. Sorensen has nothing to disclose. Dr. Chen has nothing to disclose. Dr. Wong has nothing to disclose. Dr. Yee has nothing to disclose. Dr. Ke has nothing to disclose. Dr. Rose has received personal compensation from Boehringer Ingelheim for speakers bureau services. Dr. Grosvenor has nothing to disclose. Dr. Bedenk has nothing to disclose. Dr. Fernandes has nothing to disclose. Dr. Tong has nothing to disclose.
Source: Neurology - Category: Neurology Authors: Tags: Thrombolysis and Acute Evaluation in Ischemic Stroke Source Type: research